BIOLOGICAL
SCIENCES
Advancing humanity's understanding of biology across worlds. From the identification of the genetic basis for 98% of human cancers to the cataloging of over 12,000 exo-biological species, our research is unlocking the potential of life itself for the benefit of all humankind.
ADVANCING HUMAN
KNOWLEDGE
As humanity expands beyond Earth, we encounter biological systems of extraordinary diversity and complexity. The Biological Sciences Division exists to study, understand, and responsibly harness these discoveries for the advancement of human medicine, agriculture, and environmental science.
Our researchers operate at the frontier of knowledge, documenting life forms never before seen by human eyes, identifying compounds with transformative pharmaceutical potential, and developing the biological frameworks necessary to sustain human populations on worlds vastly different from our own.
Every discovery is guided by our unwavering commitment to responsible research practices, regulatory compliance, and the ethical pursuit of knowledge that benefits all of humanity.
CANCER GENETIC CHAIN IDENTIFICATION
In 2022, our Advanced Genetics team identified the complete genetic chain responsible for 98% of all known human cancers. This breakthrough laid the foundation for targeted gene therapy protocols now in clinical deployment across Earth and colony healthcare systems.
$ biosci --division-status
RESEARCH STATIONS: 214 ACTIVE
FIELD TEAMS: 892 DEPLOYED
ACTIVE STUDIES: 3,400+
PUBLICATIONS (YTD): 1,247
PATENT FILINGS (YTD): 89
$ STATUS: ALL SYSTEMS NOMINAL_
RESEARCH AREAS
EXO-BIOLOGICAL SURVEY
Comprehensive cataloging and analysis of biological systems encountered across colony worlds. Our field teams have documented over 12,000 unique species, contributing to the largest xenobiological database in human history.
GENETIC ADAPTATION RESEARCH
Studying how terrestrial organisms can be modified for survival in non-Earth environments. Applications include crop strains for colony agriculture, livestock adaptation, and human genetic resilience enhancement.
PHARMACEUTICAL DEVELOPMENT
Discovery and synthesis of novel pharmaceutical compounds derived from exo-biological sources. Our pipeline includes 200+ compounds in various stages of clinical trial, targeting conditions from neurodegeneration to radiation exposure.
ENVIRONMENTAL BIOLOGY
Ecosystem design and management for terraformed worlds. Developing microbial seeding protocols, soil formation accelerators, and atmospheric biological agents to support long-term planetary habitability.
PATHOGEN DEFENSE
Identification, containment, and countermeasure development for biological threats encountered in extra-solar environments. Ensuring colony populations remain protected from novel biological hazards.
ADVANCED GENETICS PROGRAM
Classified research program operating under Special Order oversight. Advancing humanity's understanding of non-terrestrial genetic architectures and their potential applications.
RESEARCH ETHICS
All biological research conducted under the Weyland-Yutani corporate umbrella adheres to the highest standards of ethical oversight. Our Institutional Review Board, comprising independent scientists, ethicists, and community representatives, reviews every research protocol before approval.
We maintain full compliance with the Interstellar Commerce Commission Biological Research Standards (ICC-BRS), the Earth Biological Safety Convention (EBSC), and all applicable colonial governance regulations regarding the study and handling of biological materials.
Transparency, accountability, and the responsible stewardship of knowledge are foundational to everything we do. Our annual Research Ethics Report is available to all stakeholders and regulatory bodies upon request.
INSTITUTIONAL REVIEW BOARD
Independent oversight body reviewing all research protocols. Comprising 15 members including external scientists, bioethicists, legal counsel, and community representatives.
ICC COMPLIANCE
Full adherence to Interstellar Commerce Commission Biological Research Standards. Annual compliance audits conducted by independent third-party assessors. Zero violations on record.
BIOSAFETY PROTOCOLS
All facilities maintain appropriate biosafety containment levels (BSL-1 through BSL-5). Comprehensive decontamination, quarantine, and emergency response procedures at every research station.
WHISTLEBLOWER PROTECTION
Weyland-Yutani maintains a confidential ethics reporting channel available to all personnel. Full legal protection for individuals reporting concerns in good faith.
KEY MILESTONES
DIVISION ESTABLISHED
Biological Sciences Division formally constituted within Weyland Industries corporate structure.
FIRST EXOBIOLOGY LAB
Orbital research facility commissioned for zero-gravity biological experimentation and sample analysis.
CANCER GENETIC CHAIN
Identification of the genetic chain responsible for 98% of all human cancers. Foundation for targeted gene therapy.
10,000 SPECIES CATALOGED
Exo-biological survey teams reach milestone of 10,000 unique non-terrestrial species documented and archived.
FIRST COLONY PHARMA PLANT
Pharmaceutical manufacturing facility established on LV-271 for local production of colony-specific medications.
PATHOGEN DEFENSE CENTER
Advanced biosafety level 5 research center operational for study of high-risk biological materials.
FIELD RESEARCH EXPANSION
200+ permanent research stations established across colony worlds for continuous biological monitoring.
FIELD OPERATIONS
Our research teams operate across the full breadth of human-explored space, from orbital laboratories to deep-frontier field stations on newly surveyed worlds.
PERMANENT STATIONS
Fully equipped research facilities across colony worlds with BSL-3+ containment capability.
FIELD TEAMS
Mobile research units deployed for survey missions, sample collection, and environmental monitoring.
ORBITAL LABS
Zero-gravity and controlled-environment research platforms for specialized experimentation programs.
EXPLORE THE UNKNOWN
Join our research teams in advancing humanity's understanding of life across the galaxy.